IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3998
Positioning
Market Dominance
Manufacturing
Chemicals
$4M
David Palach
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = NITO ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$NITO N2OFF, Inc. | 36 | 19 | 36 | 67 | 2.0x | 2.6x | -88.8% | -69.9% | 39.4% | -33618.9% | 8297.7% | -87.9% | 0.0% | 27.0x | $4M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
N2OFF, Inc. (NITO) receives a "Avoid" rating with a composite score of 36.1/100. It ranks #3998 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
David Palach
Chief Executive Officer
Labor Force
2
19
33
5
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NITO
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for NITO.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -88.8% (sector -2.5%)
GM 39% vs sector 43%, OM -33619% vs sector 1%
Capital turnover N/A, R&D intensity 122.7%
Rev growth -88%, 7yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags N2OFF, Inc. with an Avoid rating, assigning a composite score of 36.1/100 and 1 out of 5 stars. Ranked #3998 of 7,333 stocks, NITO falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
N2OFF, Inc. registers a weak quality score of just 19/100, indicating significant profitability challenges. The company reports a return on equity of -88.8% (sector avg: -2.5%), gross margins of 39.4% (sector avg: 42.5%), net margins of 8297.7% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 36/100, NITO appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 1.96x, an EV/EBITDA of 2.61x, a P/B ratio of 0.29x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
N2OFF, Inc.'s investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -87.9% vs. a sector average of 5.9% and a return on assets of -69.9% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NITO demonstrates moderate momentum with a score of 67/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -87.9% year-over-year, while a beta of 5.11 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
N2OFF, Inc. registers a low stability score of 5/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 5.11 and a debt-to-equity ratio of 27.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 49/100 for NITO suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 5.11), elevated leverage (D/E: 27.00x), micro-cap liquidity risk. With a $4M market cap (micro-cap), N2OFF, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
N2OFF, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3998 of 7,333 overall (45th percentile). Key comparisons include ROE of -88.8% trailing the -2.5% sector median and operating margins of -33618.9% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NITO currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (5) would have the largest impact on the composite score.
EV/EBITDA 77% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 3483% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 7% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate N2OFF, Inc. (NITO) as Avoid with a composite score of 36.1/100 at a current price of $0.86. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (67th percentile) and value (36th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (5th percentile) and quality (19th percentile) tempers our overall conviction. We assign a No Moat rating (22/100), High uncertainty, and Poor capital allocation.
Key items to watch: whether strong momentum is fundamentally supported by revenue trends. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
N2OFF, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 36.1/100 places it at rank #3998 in our full 7,333-stock universe. At $4M in market capitalization, N2OFF, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Despite positive momentum (67th percentile), revenue contraction of -88% creates a divergence between price action and fundamental trajectory. This divergence suggests either that the market is looking through near-term weakness or that technical factors are temporarily inflating the stock. Investors should assess whether the revenue decline reflects cyclical weakness or structural challenges.
The margin cascade tells an important story: gross margins of 39% (-3.1pp vs sector) narrow to operating margins of -33619% (-33620.2pp vs sector) and net margins of 8297.7%, yielding a gross-to-net conversion rate of 21063%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $0.86, N2OFF, Inc. is trading at a premium to fundamental value. Our value factor score of 36/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 2.0x (a 91% discount to the sector median of 22.3x), EV/EBITDA of 2.6x (discounted to peers), P/B of 0.3x, P/S of 315.4x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
A conservative balance sheet (27% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Positive momentum (67th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Avoid rating (composite 36.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -88% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Below-average quality (19th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to N2OFF, Inc.. Key risk factors include elevated market sensitivity (beta of 5.11), below-average price stability (5th percentile), weak quality scores (19th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 5.11); below-average price stability (5th percentile); weak quality scores (19th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 5th percentile and quality factor at the 19th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (27% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate N2OFF, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-88.8%), weak asset returns (ROA -69.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — N2OFF, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, N2OFF, Inc. receives a Avoid rating with a composite score of 36.1/100 (rank #3998 of 7,333). Our quantitative framework assigns a No Moat (22/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 32/100.
Our analysis does not support a constructive view on N2OFF, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign N2OFF, Inc. a meaningful economic moat, scoring 22/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, reinvestment efficiency, reached only 7/20.
The strongest moat sources are reinvestment efficiency (7/20) and financial resilience (6.1/20). Capital turnover N/A, R&D intensity 122.7%. Interest coverage N/A. These pillars form the core of N2OFF, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include growth durability (2/20) and economic value creation (2.5/20). Rev growth -88%, 7yr history. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect N2OFF, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 39% providing a solid profitability foundation, declining revenues (-88%) that pressure the earnings outlook. The margin cascade from 39% gross to -33619% operating to 8297.7% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 19th percentile.
The margin profile shows gross margins of 39%, operating margins of -33619%, net margins of 8297.7%. Return metrics include ROE of -88.8% and ROA of -69.9%. Relative to the Manufacturing sector, gross margins are 3.1 percentage points below the sector median of 43%, and ROE of -88.8% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 27%, revenue growth of -88%. The sector median D/E is 0%, putting N2OFF, Inc. at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
High beta of 5.11 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081

N2OFF (NASDAQ: NITO) highlighted a recent peer-reviewed study, co-authored by Prof. Ciro Leonardo Pierri, a co-founder of its subsidiary MitoCareX Bio Ltd., that investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for spaceflight-induced dysfunctions. The study, published in the Journal of Translational Medicine, aligns with MitoCareX Bio's focus on mitochondrial carrier biology and its MITOLINE™ platform for drug discovery. Despite the scientific announcement, NITO's stock declined by 7.94%, reflecting a negative market reaction.

N2OFF, Inc. (NASDAQ: NITO) announced a new peer-reviewed study, co-authored by Prof. Ciro Leonardo Pierri of its subsidiary MitoCareX Bio Ltd., published in the Journal of Translational Medicine. The study investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions caused by spaceflight, such as those related to microgravity and cosmic radiation. This research aligns with MitoCareX Bio's focus on developing small-molecule drugs targeting these mitochondrial carriers for various diseases.
N2OFF, Inc. (NASDAQ: NITO) has completed its acquisition of MitoCareX Bio Ltd., a biotechnology company focused on precision oncology drug discovery. MitoCareX, utilizing its proprietary MITOLINE™ algorithm, aims to develop novel therapies for aggressive cancers like lung and pancreatic cancer by targeting mitochondrial transport proteins. The company has outlined strategic plans for 2026, including optimizing drug candidates and exploring collaborations to generate non-dilutive revenue and advance toward clinical readiness.
Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly

N2OFF Inc. (NITO) stock has surged by 14.55% following the announcement of a "game-changing partnership deal," driven by increased trading volumes and positive market sentiment. Despite impressive gross margins, negative profit margins indicate challenges, yet strong quick and current ratios suggest financial stability. The article emphasizes that NITO's performance reflects broader market trends and investor confidence, with strategic decisions playing a crucial role in its volatile stock landscape.